Kamal Abbi, MD
Medical Oncology · Green Bay, WINPI 1588827778
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $270 of the $390 with a category attached, or 69.4%. 8 manufacturers reported payments, led by AbbVie at 28.6% of the total.
Across 8 payments — averaging $48.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$111
- Vertex$96
- Amgen$95
- Takeda Pharmaceuticals U.S.A., Inc.$30
- Jazz Pharmaceuticals Inc.$28
- Karyopharm Therapeutics Inc.$12
- plus $17 from 2 others
Across 6 payments — averaging $3500.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$20K
- Merck$1K
What the payments were for
- Food & beverage$27069%
- Education$11931%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $111 |
| Vertex | 1 | $96 |
| Amgen | 1 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| Gilead | 1 | $12 |
| Array Biopharma Inc | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Venclexta$111
How this compares
$390 in reported general payments places this provider in the 55th percentile of 54 medical oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 17 | $306,749 |
| AlecensaAlectinib Hcl | 11 | $236,758 |
| BrukinsaZanubrutinib | 13 | $183,285 |
| IbrancePalbociclib | 15 | $171,150 |
| Lenalidomide | 13 | $165,965 |
| EliquisApixaban | 96 | $75,768 |
| Abiraterone Acetate | 51 | $57,632 |
| XareltoRivaroxaban | 14 | $15,823 |
| Tamoxifen Citrate | 62 | $1,284 |
| Potassium Chloride | 24 | $1,252 |
| Prochlorperazine Maleate | 102 | $1,177 |
| Anastrozole | 57 | $932 |
| Dexamethasone | 62 | $876 |
| Duloxetine Hcl | 12 | $767 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 23 | $700 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Green Bay
- Alexander StarrGreen Bay$903
- Hassan TahsildarGreen Bay$459
- Ruth WarrenGreen Bay$282
- Maria de VillaGreen Bay$141
- Gerald BayerGreen Bay$88
- David GroteluschenGreen Bay$32
- Thomas SaphnerGreen Bay$22
- Alexandria PhanMilwaukee$260K
- Joshua LangMadison$114K
- Dustin DemingMadison$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.